No Data
Optimistic Investors Push Shanghai Haixin Group Co., Ltd. (SHSE:600851) Shares Up 28% But Growth Is Lacking
Shanghai Haixin Group (600851.SH): The application for participation in the development of Sutent capsules was recently completed by a subsidiary and included in the list of breakthrough therapeutic drugs published by the drug evaluation center.
On August 6th, Gelunhui reported that Shanghai Haixin Group (600851.SH) stated on the investor interaction platform that the application for Malay acid sunitinib capsules submitted by its holding company, Jiangsu Suzhong Traditional Chinese Medicine Group Co., Ltd., has recently been included in the public announcement of breakthrough therapeutic drugs by the Drug Evaluation Center of the National Medical Products Administration. At present, the drug is still in Phase II clinical trials and will not have a significant impact on the company's operations and performance. The development of new drugs has a long cycle, requires significant investment, and involves high risk, with many unpredictable factors and a high degree of uncertainty. We urge investors to make cautious decisions and be mindful of investment risks.
Retail Investors in Shanghai Haixin Group Co., Ltd. (SHSE:600851) Are Its Biggest Bettors, and Their Bets Paid off as Stock Gained 7.1% Last Week
Shanghai Haixin Group (600851.SH): annual equity distribution of 10 dividends of 0.65 yuan in 2023, ex-dividend date of July 31.
On July 24, Gelunhui reported that Shanghai Haixin Group (600851.SH) announced the 2023 annual equity distribution plan: based on a total share capital of 1,207,056,692 shares before the implementation of the plan, a cash dividend of 0.065 yuan per share (including tax) will be distributed, with a total cash dividend of 78,458,684.98 yuan. The A-share equity distribution registration day for this time will be July 30, 2024, and the ex-rights and ex-dividend day will be July 31, 2024.
Shanghai Haixin Group (600851.SH): Plans to liquidate and cancel Shanghai Jinshuo Real Estate Co., Ltd.
On June 26th, Gelunhui reported that Shanghai Jinshuo Real Estate Co., Ltd. (referred to as 'Jinshuo Real Estate') was established in May 2005 with a registered capital of 3 million yuan. Shanghai Haixin Construction Development Co., Ltd. (referred to as 'Haixin Construction'), a wholly-owned subsidiary of Shanghai Haixin Group, holds a 20% equity stake in Jinshuo Real Estate. Jinshuo Real Estate currently has no actual business operations, so it is planned to be liquidated and cancelled. Haixin Construction is expected to be able to distribute approximately 2.2 million yuan of funds after liquidation (subject to the actual distribution amount at the time of business registration cancellation).
Does Shanghai Haixin Group (SHSE:600851) Have A Healthy Balance Sheet?
Shanghai Haixin Group Co., Ltd.'s (SHSE:600851) Share Price Not Quite Adding UpNo Data
